Post-hoc of ARASENS for metastatic hormone sensitive prostate cancer

A post-hoc analysis of data from ARASENS trial supplied more info about the efficacy of triplet therapy.

In summary:

  1. Robust PSA Response: A substantial percentage of patients reached undetectable PSA levels (<0.2 ng/ml), with 67% achieving this at some point. Results varied by subgroup, with 62% in high-volume and 84% in low-volume disease achieving undetectable levels.
  2. Extended PSA Progression-Free Time: Darolutamide significantly delayed PSA progression, with hazard ratios showing marked reductions in risk across both high- and low-volume groups.
  3. Clinical Impact of PSA Suppression: Sustained low PSA levels strongly correlated with longer overall survival and a delayed transition to castration-resistant prostate cancer (CRPC), especially when undetectable PSA was maintained by weeks 24 and 36.
  4. Safety Profile: The combination therapy was well-tolerated, with expected side effects consistent with those typically associated with these treatments.

Source data